HWHG(600079) 证券时报网·2025-01-16 01:15Core Viewpoint - The restructuring of Wuhan Contemporary Technology Industry Group Co., Ltd. (referred to as "Contemporary Technology") is set to change the control of Renfu Pharmaceutical, with China Merchants Innovation Technology (referred to as "China Merchants Innovation") investing a total of 11.8 billion yuan to become the controlling shareholder [1][2][4]. Group 1: Investment and Restructuring - China Merchants Innovation has signed an agreement to become the restructuring investor for Contemporary Technology, with a total investment of 11.8 billion yuan [1][3]. - The restructuring process was initiated by the Wuhan Intermediate People's Court, which accepted the restructuring application on September 30, 2024 [2]. - A total of six qualified restructuring investors, including three central enterprises and three local state-owned enterprises, participated in the bidding process, with China Merchants Innovation ranking first in the evaluation [2][3]. Group 2: Impact on Renfu Pharmaceutical - The restructuring of Contemporary Technology is expected to alleviate market concerns regarding Renfu Pharmaceutical, which has been affected by Contemporary Technology's debt crisis since 2022 [1][4]. - Renfu Pharmaceutical is positioned as a leading player in the pharmaceutical sector, and the partnership with China Merchants Group is anticipated to provide additional resource support [1][3]. - The company has maintained a strong independent position despite the financial issues of its major shareholder, Contemporary Technology [5]. Group 3: Financial Performance - Renfu Pharmaceutical reported a revenue of 19.143 billion yuan for the first three quarters of 2024, reflecting a year-on-year growth of 5.7%, and a net profit of 1.521 billion yuan, up 1.21% year-on-year [6]. - The company has consistently maintained revenues above 20 billion yuan and net profits exceeding 1 billion yuan since 2020, showcasing its robust financial health [6].